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Dr David P. Mason (Cleveland, Ohio). Dr Mulloy, congratula-
tions on an impressive experiment and presentation. It is obvious
you put a lot of thought into the study design, and I am certain
the execution took a great amount of patience, as well as technical
expertise. I do not have any criticisms, although I do have 3
questions.
My first question. You designed a model of Maastricht category
I non–heart-beating donation with a 1-hour period of no-touch
warm ischemic time. Most lung transplantation performed
throughout theworld and all of it in the United States is withMaas-
tricht category III donors, which have a much shorter no-touch
time. Could you explain why you chose this model when it seems
that even category III donors are underutilized?
My second question pertains to the use of systemic heparin. In
your model, you gave no systemic heparin to the donor, and at har-
vest you noted a large amount of clot that you made great efforts to
remove. I wonder what role microscopic thrombosis played in
your graft function? Did you note any microscopic thrombi on his-
topathologic examination after animal death?
My last question. Your finding that immediate EVLP performed
worse than delayed EVLP is surprising. You suggest that this is ex-
plained by the protective effect of hypothermia that is better
achieved in the delayed EVLP during the 4-hour waiting period
on ice. After flushing with cold Perfadex, did the immediate
EVLP group receive any time on ice?
Thank you very much, and an excellent presentation and study.
Dr Mulloy. Thank you Dr Mason, for your kind comments and
excellent questions. I will answer them in the order that you asked.
The first question regarding why we chose Maastricht category I
versus III. Based on the experience from the Toronto group, we
know thatMaastricht category III lungs can be successfully assessed
and rehabilitated for subsequent transplantation using EVLP. In
their human clinical trial published last year, the Toronto group
showed that recipients of category III lungs that were assessed by
EVLP had equivalent clinical outcomes to standard lung transplant
recipients. Thus, we really designed this study as a ‘‘proof of con-
cept’’ study to demonstrate that uncontrolled Maastricht category
I donors could also be rehabilitated for successful transplantation.
That is why we chose a relatively longer ischemic time of 60 min-
utes, basically with the idea that if we could recondition these lungs
with extended warm ischemic times for successful transplantation,
we would prove that a significant proportion of uncontrolled non–
heart-beating donor lungs could be reconditioned.
Second, although the Maastricht category III donors are surely
underused, just from a pure numbers standpoint, the use of cate-
gory I donors would go much further toward solving the donor or-
gan shortage. Several hundred thousand people each year die of
cardiac arrest, and if we could use even 1% of those lungs, it would
go a long way toward solving the donor organ shortage.
Regarding the second question about the lack of heparin dosing
and the presence of microscopic thrombi, it is a great question, be-
cause thrombosis definitely did play a role in our study. At lung ex-
plantation, we did note clot both in the left atrium and in the
pulmonary veins, and we made all efforts to remove that clot.
However, clearly we were not able to remove all the clot, and I
am sure there was additional clot in the capillaries and smaller
vessels that we were unable to even visualize. I asked ourdiovascular Surgery c Volume 144, Number 5 1215
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Xhistopathologist about the presence of thrombi, and he did not no-
tice any mature fibrin thrombi in any of our samples. That being
said, the EVLP-treated lungs had heparin added to the acellular
perfusate, and also our recipient pigs were heparinized during
the 4-hour reperfusion period. Thus, I think the heparin during
the EVLP perfusion and recipient reperfusion likely dissolved
any existing thrombi, and I suspect that if we looked at the lung
histopathologic features immediately at explantation, we would
see extensive microscopic thrombi.
In fact, probably 1 of the great benefits of EVLP is that during
the acellular perfusion period you can treat with heparin to dis-
solve any existing clot in these uncontrolled donors.
Finally, the last question about whether the immediate group re-
ceived any hypothermia, the short answer to that question is yes.
After lung explantation, all lungs were taken to the back table
and flushed retrogradewith additional Perfadex. For the immediate
EVLP group, we then sewed in the EVLP cannulas as quickly as
possible, but that did take an average of 22 minutes. During that
period, the lungs were immersed in cold Perfadex; however, for ex-
posure reasons, they were not completely immersed. Thus, it was
really 22 minutes of partial hypothermia. In this study, obviously,
those 22 minutes of partial hypothermia were not adequate. Were
the full 4 hours of hypothermia used in the D-EVLP group before
EVLP necessary? Probably not. It is probably some period in the
middle that is needed to achieve the observed beneficial hypother-
mic effect.
Dr Michael J. Weyant (Aurora, Colo). I thought your presen-
tation was excellent and your project is very interesting. I had
a couple of questions, and I realize that you will probably touch
on these in later papers. Regarding the adenosine agonist treat-
ment. I did not notice whether you had given any in your flush
in your control group and whether you think that this plays
a role in the successful outcome of the long-term EVLP group,
and second, whether you did any analysis looking at whether the
receptors were downregulated or not in your specimens. I am
sure that you are planning on doing these. I am just curious to
know.
Dr Mulloy. Thank you for that question. I am sure a lot of you
know that our group has a long history of investigation into the use
of adenosine agonists in lung ischemia–reperfusion injury.
We did add the adenosine 2A receptor agonist to the flush in all
groups, and both of the EVLP groups received adenosine 2A ago-
nist dosing during EVLP. Therefore, we did not have an untreated
control group that would allow us to make specific statements
about the role of the adenosine-2A agonist in this study. We re-
cently published a study showing that the adenosine 2A agonist
prevented the ischemia–reperfusion injury related to lung trans-
plantation.We have also published our experience using a selective
adenosine 2A agonist during EVLP in a nontransplant porcine
model and demonstrated lung protection during EVLP with aden-
osine 2A receptor agonist. So again, with the present study de-
signed mainly as a proof-of-concept study, we opted to add the1216 The Journal of Thoracic and Cardiovascular Suradenosine 2A agonist to all groups. Now that we have proved
the concept, we plan to perform additional studies in which we
will have appropriate controls to determine exactly what the role
of the adenosine 2A agonist is in this model. Finally, we did not
check receptor upregulation or downregulation in this study but
plan to do so in future studies.
Dr Todd Rosengart (Stony Brook, NY). Congratulations on
a great study, a great circumstance in which an unexpected result
raises more questions than you anticipated. I think the obvious
question is, have your results begat the additional experimental
group of immediate cold reperfusion with or without agonists?
Is this something you have contemplated or done already, and if
not, what would you expect to find with that?
DrMulloy.Wehave not discussed performing cold reperfusion.
I think 1 of the lessons learned in this study is that we obtained ex-
cellent lung function from the delayed EVLP group. Thus, perhaps
with the additional use of EVLP, the standard cold static preserva-
tion period is not as damaging as is generally thought and could
probably be extended a little bit longer in many circumstances.
In my mind, the future translation of these results would be to
transport donor lungs on ice, then place them on normothermic
EVLP at certain centers that specialize in lung assessment and re-
habilitation, and then send them back out on ice to individual hos-
pitals for subsequent transplantation. However, regarding the role
of cold perfusion, we have not discussed that because we believe
that hypothermia is important for suppression of the inflammatory
response but does not allow for true rehabilitation or appropriate
functional assessment.
Dr Fabio De Robertis (Harefield, United Kingdom). Thank
you. I enjoyed your presentation very much. Congratulations for
your study.
That you did not administer systemic heparin is actually match-
ing what happens in the clinical setting in the United Kingdom.We
cannot heparinize the donor who experienced cardiac death. In the
clinical setting, we use category III or IV donors. But did you add
any heparin in the flush? Did you add anything else in the flush?
Did you use prostaglandin? The second question is: did you do
any retrograde flush, as well as antegrade flush? Did you use any-
thing else in the flush? Did you use prostaglandin? How did you do
that?
My third question is: of the lungs that did not improve in func-
tion, did you x-ray them, and if you did, what were the findings?
Dr Mulloy. I will answer your last question first. We did not x-
ray the lungs because we do not at this time have x-ray capabilities
in our animal operating theater.
Regarding the use of heparin, we did add 10,000 IU of heparin
to the Perfadex flush and also performed a retrograde flush. We
also infused prostaglandin E1 into the pulmonary artery immedi-
ately before starting the flush. However, even with those maneu-
vers, there was still clot present. When we placed the lungs on
EVLP, we would see clots continue to come out of the lungs for
the first 15 to 30 minutes.gery c November 2012
